Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM09 allergoid-mannan conjugates for house dust mite allergic asthma and rhinitis
2021-003014-39Phase 3Terminated
- Sponsor
- Inmunotek
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Clustoid MM09 in allergic asthma, allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and 1 more (4 arms), sponsored by Inmunotek. Primary endpoint: Combined score of symptoms and medication consumption throughout the trial, for both asthma and rhinitis/rhinoconjunctivitis. Started Oct 2021; status: terminated.
02
Drugs
Clustoid MM09
03
Conditions
allergic asthmaallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2021-003014-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003014-39.